Skip links

A growing portfolio of novel medicines addressing targets and pathways critical in neurodegenerative and other CNS disorders

What is Neurodegeneration?

Brain diseases affecting mind and body, represent a major societal burden impacting patients of all age, gender, and ethnicity. SciNeuro is dedicated to developing medicines for neurological diseases with a specific focus on neurodegenerative diseases in which the structure and function of neurons are progressively damaged and lost. As a result, patients lose their natural ability to move, speak, remember, or think. Neurodegeneration can present in various forms, such as Parkinson’s disease (PD) and Alzheimer’s disease (AD), two common neurodegenerative diseases affecting more than 65 million patients worldwide, as well as rare conditions like amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).

Pipeline Strategy

In recent years, the rapid progress of human genetic, genomic, and biomarker studies have revealed molecular and pathological culprits of neurodegeneration, nominating promising therapeutic targets.

More research now provides scientific details revealing drivers of neurodegeneration in key related pathways highlighting proteinopathy, neurovascular inflammation, and immune response. We have developed specific strategies to target each of these mechanisms:

Proteinopathy arises from accumulation of misfolded and toxic proteins such as β-amyloid or α-synuclein, disrupting neuron structure and key cellular function. We are developing potent therapeutic molecules that bind and remove these disease-causing proteins. As a result, the therapy will alleviate neurotoxicity and slow down or halt neuron death.

Blood carrying oxygen and nutrients to the brain is essential for neuron health. Reduced blood flow and leaky blood-brain barriers are common events in neurodegeneration such as Alzheimer’s disease and vascular dementia. We are developing first-in-class molecules that repair vascular defects, restoring healthy blood flow to the brain.

Our body’s immune cells react to intrinsic cellular changes or foreign pathogens by launching appropriate responses. In neurodegenerative diseases, too little or too much response from brain microglia or periphery immune cells aggravates neuron damage and loss. Our approach is to promote protective immune response while curb harmful pro-inflammatory cues with potent and selective therapeutic molecules.